Delcath Systems, Inc. (DCTH) NASDAQ
10.53
-0.07(-0.66%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Delcath Systems, Inc.
Address
1633 Broadway
New York City, NY 10019
United States of America (the)
Phone
212 489 2100
Website
Sector
Healthcare
Industry
Medical - Devices
Employees
96
First IPO Date
May 03, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Gerard J. Michel | Chief Executive Officer & Director | 990,707 | 1963 |
| Kevin Muir | Chief Commercial Officer | 394,402 | N/A |
| Johnny John | Senior Vice President of Clinical Operations & Medical Affairs | 472,163 | 1965 |
| Martha S. Rook | Chief Operating Officer | 640,833 | 1971 |
| Vojislav Vukovic | Chief Medical Officer | 672,000 | 1967 |
| Sandra Pennell | Chief Financial Officer | 0 | 1979 |
| Michael Brunner | Senior Vice President of Interventional Oncology | 0 | N/A |
| David Hoffman | General Counsel, Corporate Secretary & Chief Compliance Officer | 0 | 1970 |
Description
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
